Salt Lake City, Utah
Company Collaborations
INFO
Purgo Scientific, LLC has developed a new medical device for the treatment of surgical site infection (“SSI”). Our initial target market is surgeries involving SSI related to orthopedic hardware – a devastating problem that is estimated to cost the US healthcare system $10billion per year. The patent-issues device was developed by a professor at the University of Utah who is one of the leading scientists in the world in the identification, prevention, and elimination of bacteria in biofilm. The device enables a very targeted method of delivering drugs to areas of infection and it will have subsequent applications in other treatments including oncology and pain management.
Curza is a small-molecule therapeutics company that has developed several structurally distinct classes of proprietary drugs focused on infectious diseases and oncology. Curza’s lead program is a new class of broad-spectrum antibiotics, focused on ESKAPE pathogens and drug-resistant Gram-negative bacteria. Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome. With ever-increasing reports of resistance to frontline therapies addressing Gram-negative bacteria, there is a critical need for new therapies and new therapies that work in new ways. However, very little can be found in the development pipeline. As a result, Curza’s compounds are addressing a major unmet medical need.
IN
